Cardinal Health (CAH) Q2 2026 Earnings
How Did CAH Stock React to Q2 2026 Earnings?
S&P 500 over the same 30 days: −0.06%.
Did CAH Beat Earnings? Q2 2026 Results
Yes. Cardinal Health reported Q2 2026 earnings of $2.63 a share on Feb 5, 2026, beating the $2.37 consensus estimate by 11.2%. Revenue was $65.6B against a $65.2B estimate.
Cardinal Health delivered a strong fiscal second-quarter 2026 result, posting non-GAAP diluted EPS of $2.63 against a consensus estimate of $2.37, a beat of 11.17%, while revenue of $65.63 billion edged past estimates by 0.60% and grew 18.8% year over year. The primary engine behind that top-line acceleration was the Pharmaceutical and Specialty Solutions segment, which expanded 19% to $60.67 billion on robust brand and specialty pharmaceutical volumes from both existing and new customers, accounting for the overwhelming majority of consolidated sales. Non-GAAP operating earnings climbed 38% to $877 million, reflecting meaningful operating leverage alongside a reduced share count, partially offset by higher interest costs tied to acquisition financing. The Global Medical Products and Distribution segment also contributed positively, with segment profit more than doubling to $37 million on cost optimization progress. Analysts have noted the quarter reinforces Cardinal Health's standing as a compelling large-cap healthcare distributor. Management raised its fiscal 2026 non-GAAP diluted EPS guidance to a range of $10.15 to $10.35, representing 23% to 26% growth, while lifting profit outlooks across all operating segments.
- Brand and specialty pharmaceutical sales growth from existing and new customers
- Positive generics program performance
- Contributions from MSO platform acquisitions including Solaris Health
- Volume growth from existing customers in GMPD
- Cost optimization initiatives in GMPD
- Growth across at-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics
- Advanced Diabetes Supply acquisition contribution
- Lower share count from share repurchase program
“Our strong second-quarter performance reflects at least double-digit segment profit growth across all five of our operating segments.”
Cardinal Health CEO, on the earnings call
What Was Cardinal Health's Outlook in Q2 2026?
Cardinal Health raised its fiscal year 2026 non-GAAP diluted EPS guidance to $10.15 to $10.35, representing 23% to 26% growth. Pharmaceutical and Specialty Solutions segment profit growth was raised and narrowed to 20% to 22% (from 16% to 19%). GMPD segment profit was raised to approximately $150 million (from at least $140 million). Other segment profit growth was raised to 33% to 35% (from 29% to 31%). The non-GAAP effective tax rate was lowered to 21% to 23% (from 22% to 24%), and diluted weighted average shares outstanding were decreased to 237 million to 238 million.
CAH YoY Financials
| Metric | Q2 2026 | Q2 2025 | Year over year |
|---|---|---|---|
| Revenue | $65.6B | $55.3B | +18.8% |
| Gross Profit | $2.4B | $1.9B | +23.5% |
| Operating Income | $707.0M | $549.0M | +28.8% |
| Net Income | $467.0M | $400.0M | +16.8% |
CAH Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.